Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Technology appraisal guidance
Reference number: TA284
Published: 22 May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
25 March 2013
(249.92 Kb 12 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 22 March 2013